Cost-effectiveness of companion BRCA testing and adjuvant olaparib treatment in patients with BRCA-mutated high-risk HER2-negative early breast cancer

Cost-effectiveness of companion BRCA testing and adjuvant olaparib treatment in patients with BRCA-mutated high-risk HER2-negative early breast cancer

Background and objectiveAs the healthcare industry evolves towards precision medicine, methods to assess the value of integrating companion diagnostics in clinical practice through adequate reimbursement levels are becoming essential. Cost-effectiveness analysis is an established tool used to inform...

Full description

Saved in:
Bibliographic Details
Main Authors: Silviya Nikolova, Wenkang Ma, Gurdeep S. Sagoo, Yogesh Punekar, Elizabeth Sheppard
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-04-01
Series:Frontiers in Oncology
Subjects:
precision medicine
companion diagnostics
cost effectiveness analysis
targeted therapy
biomarker testing
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2025.1419071/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2025.1419071/full

Similar Items